Press Releases

 

General

  Date Title and Summary View
Oct 4, 2017
LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today announced that it will host a Research and Development (R&D) Day for investors and analysts on Thursday, October 12, 2017.  The event is scheduled to take place from 4:00 to 6:00 p.m. Eastern Time in New York City, and ...
Oct 3, 2017
100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated in Four Dose-Escalating Cohorts Clear Evidence of Biological Activity Including Dose Dependent Increases in Inflammatory Cytokines (IL-12 and IFN-g), Decreases in VEGF Levels and No Dose Limiting Toxicities Expert Advisory Board E...
Sep 27, 2017
OPTIMA Study Enrollment is Approaching 70% Independent Data Monitoring Committee Provided Unanimous Recommendation to Continue Study in August 2017 Investigators Meetings in Thailand and China Attended by 70% of Investigators in China and Asia-Pacific LAWRENCEVILLE, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN...
Aug 24, 2017
LAWRENCEVILLE, N.J., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients wit...
Aug 15, 2017
LAWRENCEVILLE, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter and six month period ended June 30, 2017 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of...
Aug 8, 2017
LAWRENCEVILLE, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxo...
Aug 7, 2017
OPTIMA Study at Over 60% Patient Enrollment, DMC Provides Unanimous Recommendation to Continue Celsion Summarizes Regulatory Strategy for ThermoDox® LAWRENCEVILLE, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committ...
Aug 4, 2017
Limited TASE Trading Activity Does Not Warrant Listing  Shares to Continue Listing and Trading on the NASDAQ Capital Market LAWRENCEVILLE, N.J., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it is taking steps to voluntarily delist the Company's common shares...
Aug 2, 2017
LAWRENCEVILLE, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced findings from the translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed...
Jul 6, 2017
LAWRENCEVILLE, N.J., July 06, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direct ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
Share This